COMP <GO>
RGEN vs ABBV // ENTERPRISE SCALE & MARKET CAP
Repligen Corporation (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: RGEN 4
— ABBV 11
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ABBV
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
market-cap
$10.69B
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
market-cap
$513.86B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 70.20% | +18.00 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 29.00% | -26.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 33.3x | +61.70 | ABBV | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 3.47% | -2.59 | ABBV | /fcf-yield <GO> |
| Operating Margin | 1.80% | 24.60% | -22.80 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 6.90% | -5.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 8.60% | -11.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 5.33 | +3.98 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | RGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 7.40% | -0.40 | RGEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 72.8 | -24.12 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 1.15 | -0.11 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 113.1x | +26.90 | ABBV | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $10.69B | $513.86B | -$503.17B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | ABBV REV | RGEN GROSS % | ABBV GROSS % | RGEN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.16B | — | 70.2% | $93.9M | $17.82B |
| FY 2024 | $0 | $56.33B | — | 70.0% | $149.7M | $17.83B |
| FY 2023 | $0 | $54.32B | — | 44.0% | $113.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
ABBV // BETA 1.15